Height- and Age-Based Dosing for Azithromycin POS and Tablets
More and more countries are completing their epidemiological mapping of trachoma in suspected
endemic districts and are preparing to distribute Zithromax® in those districts where the prevalence of
“trachomatous inflammation – follicular” (TF) is above 5% among children aged 1-9 years. Mass... drug
administration (MDA) is normally at the district level and targets the whole population with Zithromax®
tablets to those 5 years old and above; Zithromax® suspension for children between 6 months and 5
years of age; and tetracycline eye ointment 1% for infants up to 6 months old.
more
In 2018, we are celebrating 20 years of progress in eliminating trachoma, the world’s leading infectious cause of blindness. Set up in 1998 by Pfizer Inc. and the Edna McConnell Clark Foundation, the International Trachoma Initiative (ITI) supports Ministries of Health in over 30 countries around ...the world by making Zithromax® available for use in public health campaigns to eliminate trachoma. The 20th anniversary of our founding gives us an opportunity to reflect on the distance we’ve traveled in fighting this disease, and raise the ambition for accelerating to a world where diseases like trachoma are a distant memory. We have not traveled alone these past 20 years – a broad coalition of actors including NGOs, the World Health Organization (WHO), Ministries of Health, health workers, and community members have made these incredible achievements possible. Our 20th anniversary gives us an opportunity to celebrate this coalition of partners, colleagues, and friends
more
In 2011, ICTC developed a Trachoma Action Plan (TAP) planning guide to support national health officials in endemic countries. This resource was developed to complement the 2020 INSight roadmap by helping countries create specific national plans detailing how they will reach elimination targets in t...heir own particular contexts.
more
Countries, partners, and donors are committed to the global elimination of blinding trachoma by 2020.
Achieving this public health milestone requires more than funding; it requires health personnel with the
right mix of skills, and well supported and managed health systems. Mass drug administratio...n (MDA)
with Zithromax®, the Pfizer, Inc. donated antibiotic, is a key component of the SAFE strategy, endorsed
by the World Health Organization. There is growing
recognition that improving all aspects of MDA, from
planning to training, recording to reporting, and
receipt of drug to distribution (the supply chain), will
be necessary if MDA programmes are going to reduce
the community burden of Chlamydia trachomatis, and
eliminate trachoma as a cause of blindness by 2020.
more
COMMUNITY EYE HEALTH JOURNAL | VOLUME 36 | NUMBER 118 | 2023
A MANUAL FOR WASH IMPLEMENTERS, BOTSWANA
Sightsavers | Department for International Development | The International Trachoma Initiative | Children Without Worms | WaterAid | WASH Advocates | Center for Global Safe Water, Emory University | CARE USA
Trachoma is an eye infection that for thousands of years caused many people to go blind across all continents. As the result of development and targeted interventions, trachoma is now limited to an estimated 57 countries, often affecting the poorest
populations of the world. Today, more than 2 mill...ion people are either blind or suffer from a very painful disability as the result of trachoma.
more
International commitment to eliminate trachoma as a public health problem worldwide is supported by resolution WHA51.11 of the World Health Assembly .1 Important progress towards this goal has been made by harnessing the mostly informal relationships that exist between partners including Member Stat...es, the World Health Organization (WHO), academic institutions, donors and nongovernmental organizations. Recognizing that work remains to be done and that the 2020 target2 for elimination is rapidly approaching, in February 2015 the WHO Department of Control of Neglected Tropical Diseases convened a group of academic institutions that had for many years helped WHO to implement its mandate on trachoma and to work towards establishing a Network of WHO collaborating centres (WHOCCs) for Trachoma. The report of that meeting has been published.
more
ICTC’s 2022-2030 strategic plan spans the critical period running to the end of 2030, the year by which we are striving to achieve the elimination of trachoma as a public health problem. This strategic plan is in alignment with the NTD road map, Ending the neglect to attain the Sustainable Develop...ment Goals: a road map for neglected tropical diseases 2021−2030.
more
Plan stratégique 2022-2030 de l’ICTC
A key component of elimination is to reduce the number
of unmanaged trachomatous trichiasis cases to less than
1 per 1,000 population in affected areas. This will require
not only a large increase in the number of surgeries
performed, but also improvements in the quality of surgery
and in the e...fficiency of surgery provision programs. It also
will require that we make special efforts to reach out to
women and the most marginalized populations, who are
disproportionally affected by trichiasis (TT).
more
Twenty-Fourth Annual Trachoma Control Program Review, Summary Proceedings
Surveys are needed to guide trachoma control efforts in Mozambique, with WHO guidelines for intervention based on the prevalence of trachomatous inflammation–follicular (TF) in children aged 1–9 years and the prevalence of trichiasis in adults aged 15 years and above. We conducted surveys to com...plete the map of trachoma prevalence in Mozambique, concluding that it still represents a significant public health problem in many areas of Mozambique.
more
Trachoma is the world’s leading infectious cause of blindness. It is one of 18 neglected
tropical diseases (NTDs) that affect over one billion of the world’s poorest people.